DPYD Monoclonal Antibody

$Paraformaldehyde-fixed, paraffin embedded Human liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with DPYD Monoclonal Antibody, Unconjugated (bsm-54740R) at 1:200 for 30 minutes at room temperature, DAB staining.$

Paraformaldehyde-fixed, paraffin embedded Human liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with DPYD Monoclonal Antibody, Unconjugated (bsm-54740R) at 1:200 for 30 minutes at room temperature, DAB staining.

Applications

WB
IHC-P

Reactivity

Human

Overview
Catalog #	bsm-54740R
Product Name	DPYD Monoclonal Antibody
Applications	WB, IHC-P
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Synthetic peptide corresponding to C-terminal Human DPYD.
Clonality	Monoclonal
Clone #	7H9
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	1806
Swiss Prot	Q12882
Subcellular location	Cytoplasm
Synonyms	DHP antibody, DHPDHase antibody, Dihydropyrimidine dehydrogenase [NADP(+)] antibody, Dihydropyrimidine dehydrogenase [NADP+] antibody, Dihydropyrimidine dehydrogenase antibody, Dihydrothymine dehydrogenase antibody, Dihydrouracil dehydrogenase antibody, DPD antibody, DPYD antibody, DPYD_HUMAN antibody, MGC132008 antibody, MGC70799 antibody, OTTHUMP00000058954 antibody
Background	Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU. Involvement in disease: Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400